天士力(600535) - 2018 Q1 - 季度财报

Financial Performance - Operating revenue grew by 18.06% year-on-year, reaching CNY 3.95 billion, with pharmaceutical manufacturing revenue up 15.16% and pharmaceutical commerce revenue up 20.43%[5] - Net profit attributable to shareholders increased by 16.77% to CNY 371.51 million[5] - Basic earnings per share rose by 16.74% to CNY 0.3438[5] - The weighted average return on net assets increased by 0.28 percentage points to 4.20%[5] - Total operating revenue for Q1 2018 reached ¥3,952,350,207.34, an increase of 18.0% compared to ¥3,347,663,813.62 in the same period last year[29] - Net profit for Q1 2018 was ¥376,500,695.19, representing a 16.7% increase from ¥322,624,371.35 in Q1 2017[30] - Earnings per share for Q1 2018 were ¥0.3438, compared to ¥0.2945 in the previous year, reflecting a growth of 16.7%[31] Cash Flow - Cash flow from operating activities improved significantly, with a net increase of 121.04% to CNY 151.27 million compared to the same period last year[6] - Net cash flow from operating activities improved by 121.04% to ¥151,272,627.38, driven by higher receivables collection[14] - Total cash inflow from operating activities amounted to 4,728,537,775.53 RMB, while cash outflow was 4,577,265,148.15 RMB, resulting in a net cash inflow of 151,272,627.38 RMB[36] - The net cash flow from operating activities was 151,272,627.38 RMB, compared to a negative cash flow of -719,011,922.67 RMB in the previous period, indicating a significant improvement[36] - The company recorded a net cash flow from operating activities of 960,107,625.64 RMB, a substantial improvement from -327,701,910.73 RMB in the previous period[39] Assets and Liabilities - Total assets increased by 5.74% to CNY 22.77 billion compared to the end of the previous year[5] - Current assets rose to ¥16.11 billion, up from ¥15.05 billion, indicating an increase of about 7%[22] - Total liabilities decreased to ¥13.33 billion from ¥12.56 billion, a reduction of approximately 6%[23] - Short-term borrowings decreased to ¥6.11 billion from ¥6.95 billion, a decline of about 12%[22] - Long-term borrowings increased to ¥1.61 billion from ¥0.89 billion, showing a growth of approximately 80.9%[22] - The company's equity increased to ¥9.44 billion from ¥8.97 billion, representing a growth of approximately 5.2%[23] Shareholder Information - The total number of shareholders reached 28,352 at the end of the reporting period[10] - Tianjin Tianshili Holdings Group Co., Ltd. holds 45.18% of the shares, with 81.37 million shares pledged[10] Investment and Expenses - Sales expenses grew by 35.22% to ¥509,546,728.89, attributed to increased market investment and network construction[14] - Financial expenses surged by 82.76% to ¥106,821,908.24 due to an increase in interest-bearing liabilities[14] - Investment income increased by 377.72% to ¥9,110,401.06, mainly from financial management gains and equity disposal[14] - The company reported a total of CNY 12.22 million in non-recurring gains and losses for the period[11] Inventory and Receivables - Accounts receivable interest increased by 848.65% to ¥1,139,633.21 due to increased borrowings during the reporting period[13] - Other receivables rose by 51.15% to ¥355,235,684.89, primarily due to increased deposits and petty cash[13] - Goodwill increased by 31.42% to ¥181,443,915.33, mainly from the premium acquisition of Shanxi Kangmeilai[13] - The company reported a significant increase in inventory to ¥2.50 billion from ¥2.23 billion, reflecting a rise of about 12.1%[21] Strategic Developments - The company has not disclosed any new product developments or market expansion strategies in this report[5] - The company plans to restructure its biopharmaceutical segment and aims to list its subsidiary Shanghai Tianshili on the Hong Kong Stock Exchange[16] - The acquisition of 51% of Shanxi Kangmeilai was completed, with the first payment of approximately ¥69.47 million made[15] Quarterly Performance - Total operating costs for Q1 2018 were ¥3,515,008,427.83, up 19.2% from ¥2,950,121,841.60 in Q1 2017[29] - The total cash outflow for operating activities was 1,141,142,682.35 RMB, compared to 978,497,025.84 RMB in the previous period, showing increased operational costs[39] - Cash outflow for investment activities was 804,073,915.20 RMB, down from 966,157,933.86 RMB in the previous period, indicating a reduction in investment spending[39]